Vertex Stuck Between A Good Place And A Better Place

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Two three-drug regimens for cystic fibrosis hit their primary endpoints in both heterozygous and homozygous patients, with good safety and tolerability, which analysts say increases the likelihood one of them will obtain approval.

Los Angeles, California, USA - 28 February 2019: Vertex Pharmaceuticals website homepage. Vertex Pharmaceuticals logo visible on display screen, Illustrative Editorial - Image

Vertex Pharmaceuticals Inc. may not yet have certainty on which of two three-drug combination regimens for cystic fibrosis it will file for approval in the US and Europe, but it at least has options. A second three-drug combo hit the primary endpoints in a pivotal Phase III study a few months after its first trio did the same, and now Vertex says it will wait for 24-week data to decide which regimen it will file for approval.

On March 6, the Boston specialty pharma revealed that a combination of next-generation CFTR (cystic fibrosis transmembrane conductance regulator) corrector...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.